Genephit: Phosphatase Inhibition By Intracoronary Gene Therapy In Subjects With Non-Ischemic Nyha Class III Heart Failure
Posted Date: Feb 18, 2025
- Investigator: Vladimir Cotarlan
- Specialties:
- Type of Study: Drug
Scientific understanding of the molecular changes in heart failure have increased significantly in the last 20 years, and novel targets have been identified. Abnormal calcium handling plays a central role in the pathophysiology of the failing heart. Inhibitor-1c (I-1c) expression effectively reduces protein phosphatise 1 (PP1) activity in heart failure and increases phospholamban (PLN) phosphorylation resulting in improved calcium handling and cardiac function. This is a Phase 2 adaptive, double-blinded, placebo-controlled, randomized, multi-center trial study to evaluate the safety and efficacy of a single antegrade intracoronary artery infusion of NAN-101 (i.e. viral capsid expressing the transgene for I-1c) in patients with non-ischemic cardiomyopathy and NYHA Class III symptoms of HF. Subjects will be randomized into one of three treatment groups in a 1:1:1 to NAN-101 (3E13vg), NAN-101 (6E13vg, or placebo.
Criteria:
Adult Subjects With New York Heart Association (Nyha) Class Iii Heart Failure And Non-Ischemic Cardiomyopathy
Keywords:
Intracoronary Gene Therapy
For More Information:
Elias Shamieh
+1 513 558 3016
shamiees@ucmail.uc.edu